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Megakaryoblastic Termination of Myeloproliferative Disorders 
Mahul B. Amin, MD,* Koichi Maeda, MD,^  John L. Carey, MD,+ Ramesh V. Babu, PhD,* 
and B. K. S. Raman, MD^ 
Megakaryoblastic termination of myeloproliferative disorders is rare. The morphology of mega-
karyoblastic transformation can be subtle and is ofien mistaken for myeloid or lymphoid pro-
liferations. Previously reported observations suggest a relatively poor prognosis for this categoiy 
of patients, making precise diagnosis imperative. A multifaceted approach using morphology, 
ullrastruciure, cytochemistry, and immunological membrane analysis may be helpful. We presenl two 
cases of myeloproliferative disorder wilh aggressive megakaryoblastic phases (myelofibrosis with 
agnogenic myeloid metaplasia and chronic myeloid leukemia with blast crisis). The clinical course is 
described and the results oflhe morphological, cyiochemicai, ultrastructural, and cytogenetic studies 
of bolh cases are presented. In addition, immunochemical studies (flow cytometry) and platelet 
function studies (aggregation, heta-thromboglohulin, and platelet factor IV release) were done for 
one ofthese patients. (Henry Ford Hosp MedJ 1992:40:122-6) 
A cute leukemia with a predominant megakaryoblastic pro-liferation was first reported by Von Boros in 1931 and in 
North American scientific literature by McDonald in 1948 (1), 
Most of the early reported cases of megakaryoblastic prolifera-
tion were of patients who demonstrated obvious megakaryo-
cytic differentiation. Less differentiated cases may have gone 
unrecognized. The advent of cytochemistry, electron micros-
copy, and immunochemistry (immunohistochemistry and flow 
cytometry) has led to precise identification ofthese conditions. 
Neoplastic megakaryocytic/blastic proliferation may arise de 
novo, be secondary to myeloproliferative disorders and myelo-
dysplastic syndromes, or may occur as complications of con-
genital chromosomal abnormalities (chromosome 21). We pre-
sent two cases of myeloproliferative disorders, one of chronic 
myeloid leukemia (CML) and the other of primary myelofibro-
sis, with development of an accelerated phase comprised pre-
dominantly of megakaryoblasts and megakaryocytes. 
Case Reports 
Case 1 
This 63-year-old male was known to have myelofibrosis for three 
years. At diagnosis, the spleen was palpable 10 cm below the left costal 
margin. Peripheral blood morphology revealed a leukoerythroblastic 
anemia which was associated with marrow fibrosis. Results of cytoge-
netic studies were normal. The patient was treated with oral testoster-
one, followed by nandrolone decanoate (Deca-Durabolin™) intramus-
cularly and oral prednisone, to which he responded partially. Two years 
later, marrow biopsy revealed increased fibrosis. 
Three years after the diagnosis, there was a gradual increase in he-
patosplenogmegaly associated with increasing transfusion-dependent 
anemia. A red cell survival scan demonstrated destruction and short-
ened half-life. The patient underwent a splenectomy without complica-
tions. 
One month postsplenectomy, the patient developed pedal edema and 
massive hepatomegaly (20 cm below the costal margin). The hemoglo-
bin was 89 g/L, WBC count 36 x 10%, and platelet count 1.3x10%. 
A bone marrow biopsy showed 89% blasts, some of which resembled 
megakaryoblasts (Figs 1-3). Megakaryocyric differentiation was con-
firmed by electron microscopy and membrane antigen phenotyping by 
flow cytometry and by cytochemistry (Table 1, also see Figs 4-6). Cy-
togenetic studies revealed an abnormality of the long arm of chromo-
some 17: 46,XY/46,XY,i(17q) (Fig 7). The patient was started on a 
daily dose of 100 mg of hydroxyurea (Hydrea™) which was later in-
creased to 4 g. Buffy coat preparation with separation of leukocytes and 
platelets (leukapheresis and thrombocytopheresis) was pertormed. In-
terferon, 10 million units daily, was administered subcutaneously for 
two days only. The WBC and platelet counts decreased to 19 x lO'/L 
and 0.6 x IC/L, respectively. Over the next two months the patient be-
came progressively pancytopenic and eventually died of sepsis. No au-
topsy was performed. 
Case 2 
This 33-year-old male had CML which had been well controlled 
with intermittent busulfan (Myleran™) for approximately four years. 
Blast crisis was manifested by left upper quadrant pain, dyspnea, and 
fever. The spleen was strikingly enlarged and there was cervical and ax-
illary lymphadenopathy. Hemoglobin was 7.2 g/L, WBC count 261 x 
10%, and platelet count 0.6 x IC/L. Most (90%) of the nucleated cells 
in the marrow and blood were blasts. The megakaryocyte differentia-
tion was supported by morphology (light and ultrastructural) and cyto-
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Fig I—Numerous blasts with marked 
thrombocytosis (Leishman stain, 
X400). 
Fig 2—Platelets budding from blasts 
which otherwise resemble lympho-
blasts (Leishman stain, X400). 
' .^ 
Fig 3—Megakaryoblasts with multiple 
nucleoli, vacuolated cytoplasm, and 
budding platelet forms (Leishman 
stain, X2000). 
2D LIGHT SCATTEH 
0 50 
F S C — 
100 1? 0 200 250 
T o t a l = = e e m Gated= seme 
Rgn E v e r i s y. G a t e d '. T o t a l 
1 Rl 1E256 61.23 61.23 
2 R2 5096 2 5 . 4 3 2 5 . 4 8 
3 R ? 2278 1 1 . 3 9 1 1 . 3 9 
36-S; 
Fig 4—Light scatter of low density marrow mononuclear cells. 
Right; dot plot of forward (size) versus side light scatter (granu-
larity). Rl = small "lymphoid" I RBC s; R2 = large "lymphoid"; 
R3 = blasts. Fractions of cells in each area are indicated in box 
helow dot plot. Left; Three-dimensional plot of light scatter. 
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Fig 5—Expression of CD61IGPIIIa by marrow mononuclear 
cells. Left upper, middle, lower; Nonspecific fluorescence stain-
ing by FITC-conJugated negative control for theRl,R2, and R3 
populations, respectively. Right upper, middle, lower; Fluores-
cence staining hy FITC-conjugated anti-CD61 (solid histo-
grams) as compared to nonspecific fluorescence staining by 
FITC-conjugated negative control (line histograms) for the Rl, 
R2, and R3 populations, respectively. 
Fig 6—Electron microscopy of peripheral blood 
showing a megakaryoblast (X20000). 
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Fig 7—Cytogenetics 46XYI46XY, i(17g). 
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Table 1 
Results of Pertinent Hematologic Investigations 
Case 1 Case 2 
Bone Marrow: 
Initial presentation 
Impression 
Postsplenectomy 
Cytochemistry: 
PAS 
Specific estera.se 
Myeloperoxidase 
Sudan black B 
Trilineage proliferation with 
90% cellularity 
Myelofibrosis 
100% cellularity with 89% blasts 
resembling megakaryoblasts 
(Figs 1-3) 
-n-
-I- (< 5%) 
+ (< 5%) 
90% cellularity with shift to left, 
increase in myelocytes, metamyelocytes, 
band forms and mature granulocytes 
CML 
5 years later: blast crisis with 90% blasts 
showing megakaryoblastic morphology 
-I- (few) 
-I- (few) 
-I- (few) 
Membrane Analysis (Flow Cytometry) (Figs 4,5): 
CD61(GPIlIa) 90% Not done 
CD14 0% 
CD33 < 1% 
CD3 2% 
CDI3 10% (dim) 
CD 19/20 < 1% 
TdT Negative (immunocytochemistry) 
Electron Microscopy (Case 1 and Case 2): Large blasts with prominent nucleoli and cytoplasmic organelles similar to adjacent 
platelets. Morphology consistent with megakaryoblasts (Fig 6). 
Cytogenetics: 
Initial 
In blast crisis 
Platelet Funcdon: 
Aggregation 
BTG 
PD4 
(MF) Normal 
i(I7q)(Fig 7) 
ADP, epinephrine, arachidonic 
acid, ristocetin, and collagen 
were all defective 
125 lU/mL (normal 10-40 lU/mL) 
4-15 IU (normal 0-5 IU) 
(CML) Philadelphia chromosome t(9;22)(q34,q 11) 
No further abnormality developed 
Not done 
CML = chronic myeloid leukemia. MF = myelofibrosis. 
Table 2 
Identification of Megakaryoblasts 
Morphology: 
Cytochemistry: 
Ultrastructure: 
Immunohistochemistry: 
Undifferentiated blasts (lymphoid or myeloid morphology) 
Blasits with cytoplasmic budding 
Circulating micromegakaryocytes 
Increased platelets, large platelets with dysplastic forms 
Sudan black B: Negafive 
Peroxidase: Negative 
Periodic acid-Schiff: Localized, frequently positive (nonspecific) 
Acid phosphatase: Localized, frequently positive (nonspecific) 
Alpha-napthyl acetate esterase: Positive 
Alpha-napthyl butyrate esterase: Negative 
Nucleus: large, prominent nucleolus, irregular nuclear membrane, 
moderate chromatin condensation 
Cytoplasm: mitochondria, rough endoplasmic reticulum, small Golgi 
apparatus, few granules. Platelet peroxidase reaction positive (granules) 
Megakaryocytes: Alpha-granules, demarcation membranes 
CD42 (Ib), CD41 (lib), CD6I (Ilia) (suri'ace glycoproteins), factor VIII 
related antigen: Positive 
Lymphoid antigen negative (TdT, CD2,5,7,19,20) 
Monocyte antigen negative (CD 13,14) 
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chemical evidence. There was diffuse marrow fibrosis. Six courses of 
OA? (Oncovin, ara-C, and prednisone) with supplemental hydroxyurea 
over a four-month period produced only transient responses. The pa-
tient eventually died of sepsis. No autopsy was performed. The diagno-
sis was megakaryoblastic crisis of CML. 
Material and Methods 
Fresh peripheral blood and bone marrow smears and imprints 
were stained by Leishman stain. Cytochemical stains atso were 
performed: peroxidase, periodic acid-Schiff, specific esterase, 
and Sudan black B. Reticulin stain was done on biopsy speci-
mens (case 1). 
Antigen phenotyping was performed by flow cytometry and 
immunocytochemistry on peripheral blood in case 1. Monoclo-
nal antibody reagents were obtained from Coulter (CD33, 
CD 13), Becton Dickinson (CD 14,19,20), Dako (GPIIIa), and 
our institution's Molecular Genetics department (TdT). Mem-
brane immunofluorescence utilized both direct and indirect 
staining techniques. Positive/negative fluorescence gating was 
determined using fluorochrome and isotype matched monoclo-
nal negative controls. Immunocytochemistry utilized a standard 
avidin biotin technique on acetone-fixed cytopreparations. 
Cells from peripheral blood were fixed in 30% cacodylate-
buffered glutaraldehyde, pH 7.4. They were postfixed in 1% os-
mic acid and embedded in Araldite, stained with uranilacetate 
and lead citrate, and viewed with a transmission electron micro-
scope (Zeiss model 109). 
Bone marrow aspirate and peripheral lymphocytes were cul-
tured for 24 hours in medium RPMI. Cells were arrested in 
metaphase by Colcemid (D-acetyl methyl cholchicine), and af-
ter hypotonic treatment in 0.075 M KCL the material was fixed 
in 3:1 methanol;acetic acid. Metaphase cells were GTG banded 
by standard procedures. 
Platelet function tests done in case 1 included aggregation in 
response to adenosine diphosphate, epinephrine, arachidonic 
acid, ristocetin, and collagen. Beta-thromboglobulin and plate-
let factor IV tevels were determined using enzyme immunoas-
say techniques. 
The results are summarized in Tabte 1. 
Discussion 
Megakaryoblastic transformation of myeloproliferative dis-
orders is rare. It can occur in CML (2-8), myelofibrosis (2,5-
7,9), and essential thrombocythemia (10), thus reemphasizing 
the stem cell defect present in these conditions. 
The morphology of megakaryoblastic transformation may be 
subtle and often mistaken for myeloid or lymphoid morphology 
(1,4,7,11-13). Routine Romanowsky stains usually reveal un-
differentiated blasts with occasional clues towards megakary-
ocytic differentiation, such as blasts with cytoplasmic budding, 
micromegakaryocytes, or large platelets with dysplastic forms 
(6,7,9,13). Routine cytochemistry, when done, can be helpful 
but not diagnostic (13). The periodic acid-Schiff and acid phos-
phatase reactions are frequently positive with a localized reac-
tion. Alpha-naphthyl acetate esterase may be positive but the 
reaction is inhibited by the addition of fluoride. 
The megakaryocytic differentiation of the blasts can be con-
firmed by electron microscopy (3,4,10-13) and/or immunohis-
tochemistry (1,9,12). Electron microscopy reveals a large nu-
cleus, with a single large nucleolus or mulfiple nucleoli, a 
slightly irregular outline, and moderate chromatin condensation 
(12). Cytoplasm shows numerous mitochondria, large profiles 
of rough endoplasmic reticulum, a small Golgi apparatus, and a 
few granules. Circulating micromegakaryocytes will reveal al-
pha-granules and/or demarcation membranes. However, the 
Table 3 
Megakaryoblastic Transformation of Myelofibrosis 
Study 
Development of Blast Survival Post 
Age/Sex 
Primary Crisis Postsplenectomy Blast Crisis Chromosomal 
(Reference) Diagnosis Splenectomy (months) (months) Abnormality 
Efrari et al (5) 45/F MF Yes 24 1 Trisomy 9 and balanced 
(Case 1) translocation between 
chromosomes 12 and 13 
Egner et al (6) 61/M MF .^ 4 6 No abnormality 
(Case 1) 
Jacobs et al (7) 59/M MF Yes 28 31 No abnormality 
(Case 1) 
Jacobs et al (7) 60/F MF Yes 12 18 Not done 
(Case 2) 
Marcus et al (9) 36/M MF Yes 3 (approximately) 12 Not done 
(Case 1) 
Akahoshi et al (2) 60/F MF Not done 3 Duplication of the long arm 
(Case 2) of 1 and translocarion 
involving band 3q26 
Present Study 63/M MF Yes 1 3 Isochromosome for the long 
(Case 1) arm of 17 
MF = myelofibrosis. 
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most reliable confirmation of the megakaryocytic nature is dem-
onstration of platelet peroxidase activity of the granules (4,11-
14). 
Recently, antigenic analysis by immunochemical procedures 
has received much attention (1,9,12,13). The expression of 
platelet surface glycoproteins Ib (CD42), lib (CD41), Ilia 
(CD61) (11), and factor Vlll-related antigens in the absence of 
other lymphoid TdT, CD2/7, and myelomonocytic (CD 14/13) 
antigens strongly support the diagnosis of a megakaryocytic 
proliferation (15). Thus a multifaceted approach using morphol-
ogy, cytochemistry, ultrastructure, and immunochemistry may 
be necessary for precise identification (Table 2). 
Platelet functions done as in case 1 to characterize their nature 
in a megakaryoblastic proliferation showed defective aggrega-
tion to various stimuli. In addition, BTG and PF4 levels were el-
evated. These have been correlated with increased turnover with 
myeloproliferative disorder (16,17). 
There is limited cytogenetic data on megakaryoblastic blast 
crisis. Most cases with CML as a primary diagnosis had the 
same changes which are characteristic of typical blast crisis, i.e., 
4-8, second Philadelphia chromosome (3,5,8). Cases with my-
elofibrosis as a primary diagnosis had various abnormalities 
such as trisomy 9, balanced translocation between chromo-
somes 12 and 13 (5), and rearrangements involving chromo-
some band 3q26 (2). Abnormalities of 3q26 have been associ-
ated with dysmegakaryocytopoiesis (18). 
Cytogenetic studies in case 1 showed progression from nor-
mal (at time of diagnosis of myelofibrosis) to that showing an 
isochromosome for the long arm of t7:(17q). This is one of the 
characteristic changes of blast crisis of CML and has been re-
ported occasionally in patients with myelofibrosis. The observa-
tion of i(17q) as the sole, de novo abnormality is infrequent. 
Case 2 showed standard Philadelphia translocation t(9;22) 
(q34;ql 1). During blast crisis there were no other cytogenetic 
changes. About 25% of CML cases have Philadelphia transloca-
tion as the sole abnormality throughout their disease. 
The prognosis of patients with megakaryoblastic transforma-
tion is uniformly poor. In a review of the literature, Williams 
and Weiss (8) observed that seven cases of reported CML with 
megakaryoblastic transformation were all fatal, with survival 
ranging from a few days to 15 months after the transformation. 
Reported cases of myelofibrosis with similar transformations 
were also all fatal, with survival ranging from less than one 
month to 31 months (Table 3). tn patients with myelofibrosis, 
all except one case (Table 3) had undergone splenectomy which 
was followed by development of megakaryoblastic transfor-
mation from one month to 34 months postoperatively. Since 
splenectomy is often pertormed on patients with myelofibrosis, 
and the vast majority of them do not develop megakaryoblas-
tic transformation, the relationship between splenectomy and 
megakaryoblastic transformation in these cases may be merely 
coincidental. 
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